{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T01:01:41Z","timestamp":1784509301365,"version":"3.55.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002808","name":"Carlsbergfondet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008445","name":"Parkinsonforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-026-01383-y","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:26:36Z","timestamp":1778480796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Shared and distinct lipid profiles in amygdala from sporadic and GBA-associated Parkinson\u2019s diseases"],"prefix":"10.1038","volume":"12","author":[{"given":"Sonia S.","family":"Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik R.","family":"Marlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper E.","family":"Dreier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesut","family":"Bilgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista B. S.","family":"Neergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Bezard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Dehay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zane","family":"Jaunmuktane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Galvagnion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"1383_CR1","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/brain\/122.8.1437","volume":"122","author":"P Damier","year":"1999","unstructured":"Damier, P., Hirsch, E. C., Agid, Y. & Graybiel, A. M. The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson\u2019s disease. Brain 122, 1437\u20131448 (1999).","journal-title":"Brain"},{"key":"1383_CR2","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","volume":"22","author":"SH Shahmoradian","year":"2019","unstructured":"Shahmoradian, S. H. et al. Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 22, 1099\u20131109 (2019).","journal-title":"Nat. Neurosci."},{"key":"1383_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. \u03b1-Synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"1383_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nature16531","volume":"530","author":"F-X Theillet","year":"2016","unstructured":"Theillet, F.-X. et al. Structural disorder of monomeric \u03b1-synuclein persists in mammalian cells. Nature 530, 45\u201350 (2016).","journal-title":"Nature"},{"key":"1383_CR5","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.1038\/nature12125","volume":"498","author":"J Burr\u00e9","year":"2013","unstructured":"Burr\u00e9, J. et al. Properties of native brain \u03b1-synuclein. Nature 498, E4\u2013E6 (2013).","journal-title":"Nature"},{"key":"1383_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4827","volume":"5","author":"G Fusco","year":"2014","unstructured":"Fusco, G. et al. Direct observation of the three regions in \u03b1-synuclein that determine its membrane-bound behaviour. Nat. Commun. 5, 3827 (2014).","journal-title":"Nat. Commun."},{"key":"1383_CR7","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.neuron.2013.09.004","volume":"79","author":"JT Bendor","year":"2013","unstructured":"Bendor, J. T., Logan, T. P. & Edwards, R. H. The function of \u03b1-synuclein. Neuron 79, 1044\u20131066 (2013).","journal-title":"Neuron"},{"key":"1383_CR8","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1021\/ar050073t","volume":"39","author":"AL Fink","year":"2006","unstructured":"Fink, A. L. The aggregation and fibrillation of \u03b1-synuclein. Acc. Chem. Res. 39, 628\u2013634 (2006).","journal-title":"Acc. Chem. Res."},{"key":"1383_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nchembio.1750","volume":"11","author":"C Galvagnion","year":"2015","unstructured":"Galvagnion, C. et al. Lipid vesicles trigger \u03b1-synuclein aggregation by stimulating primary nucleation. Nat. Chem. Biol. 11, 229\u2013234 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"1383_CR10","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1074\/jbc.M114.585703","volume":"290","author":"M Grey","year":"2015","unstructured":"Grey, M. et al. Acceleration of \u03b1-synuclein aggregation by exosomes*. J. Biol. Chem. 290, 2969\u20132982 (2015).","journal-title":"J. Biol. Chem."},{"key":"1383_CR11","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1021\/bi061749a","volume":"46","author":"Z Martinez","year":"2007","unstructured":"Martinez, Z., Zhu, M., Han, S. & Fink, A. L. GM1 specifically interacts with \u03b1-synuclein and inhibits fibrillation. Biochemistry 46, 1868\u20131877 (2007).","journal-title":"Biochemistry"},{"key":"1383_CR12","doi-asserted-by":"publisher","first-page":"16873","DOI":"10.1074\/jbc.M210136200","volume":"278","author":"M Zhu","year":"2003","unstructured":"Zhu, M. & Fink, A. L. Lipid binding inhibits \u03b1-synuclein fibril formation*. J. Biol. Chem. 278, 16873\u201316877 (2003).","journal-title":"J. Biol. Chem."},{"key":"1383_CR13","doi-asserted-by":"publisher","first-page":"7065","DOI":"10.1073\/pnas.1601899113","volume":"113","author":"C Galvagnion","year":"2016","unstructured":"Galvagnion, C. et al. Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of \u03b1-synuclein. Proc. Natl. Acad. Sci. 113, 7065\u20137070 (2016).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"1383_CR14","doi-asserted-by":"publisher","first-page":"7872","DOI":"10.1021\/acs.jpclett.9b03005","volume":"10","author":"C Galvagnion","year":"2019","unstructured":"Galvagnion, C. et al. Lipid dynamics and phase transition within \u03b1-synuclein amyloid fibrils. J. Phys. Chem. Lett. 10, 7872\u20137877 (2019).","journal-title":"J. Phys. Chem. Lett."},{"key":"1383_CR15","doi-asserted-by":"publisher","first-page":"e77235","DOI":"10.1371\/journal.pone.0077235","volume":"8","author":"E Hellstrand","year":"2013","unstructured":"Hellstrand, E., Nowacka, A., Topgaard, D., Linse, S. & Sparr, E. Membrane lipid co-aggregation with \u03b1-synuclein fibrils. PLoS ONE 8, e77235 (2013).","journal-title":"PLoS ONE"},{"key":"1383_CR16","doi-asserted-by":"publisher","first-page":"10998","DOI":"10.1039\/D3CP05928F","volume":"26","author":"C Galvagnion","year":"2024","unstructured":"Galvagnion, C. et al. Structural characterisation of \u03b1-synuclein\u2013membrane interactions and the resulting aggregation using small angle scattering. Phys. Chem. Chem. Phys. 26, 10998\u201311013 (2024).","journal-title":"Phys. Chem. Chem. Phys."},{"key":"1383_CR17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3233\/JPD-171103","volume":"7","author":"C Galvagnion","year":"2017","unstructured":"Galvagnion, C. The role of lipids interacting with \u03b1-synuclein in the pathogenesis of Parkinson\u2019s disease. J. Parkinson\u2019s. Dis. 7, 433\u2013450 (2017).","journal-title":"J. Parkinson\u2019s. Dis."},{"key":"1383_CR18","doi-asserted-by":"publisher","first-page":"106534","DOI":"10.1016\/j.bpc.2020.106534","volume":"273","author":"SS Mu\u00f1oz","year":"2021","unstructured":"Mu\u00f1oz, S. S., Petersen, D., Marlet, F. R., K\u00fcc\u00fckk\u00f6se, E. & Galvagnion, C. The interplay between Glucocerebrosidase, \u03b1-synuclein and lipids in human models of Parkinson\u2019s disease. Biophys. Chem. 273, 106534 (2021).","journal-title":"Biophys. Chem."},{"key":"1383_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-023-00517-w","volume":"9","author":"CEG Leyns","year":"2023","unstructured":"Leyns, C. E. G. et al. Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson\u2019s disease. npj Parkinsons Dis. 9, 1\u201314 (2023).","journal-title":"npj Parkinsons Dis."},{"key":"1383_CR20","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1093\/brain\/awac176","volume":"145","author":"J Galper","year":"2022","unstructured":"Galper, J. et al. Lipid pathway dysfunction is prevalent in patients with Parkinson\u2019s disease. Brain 145, 3472\u20133487 (2022).","journal-title":"Brain"},{"key":"1383_CR21","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41582-025-01142-2","volume":"21","author":"S Fanning","year":"2025","unstructured":"Fanning, S. & Selkoe, D. Parkinson disease is a fatty acidopathy. Nat. Rev. Neurol. 21, 642\u2013655 (2025).","journal-title":"Nat. Rev. Neurol."},{"key":"1383_CR22","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1111\/febs.14393","volume":"285","author":"ME Gegg","year":"2018","unstructured":"Gegg, M. E. & Schapira, A. H. V. The role of glucocerebrosidase in Parkinson disease pathogenesis. FEBS J. 285, 3591\u20133603 (2018).","journal-title":"FEBS J."},{"key":"1383_CR23","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/mds.26616","volume":"31","author":"AHV Schapira","year":"2016","unstructured":"Schapira, A. H. V., Chiasserini, D., Beccari, T. & Parnetti, L. Glucocerebrosidase in Parkinson\u2019s disease: Insights into pathogenesis and prospects for treatment. Mov. Disord. 31, 830\u2013835 (2016).","journal-title":"Mov. Disord."},{"key":"1383_CR24","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky, E. et al. Multi-center analysis of glucocerebrosidase mutations in Parkinson disease. N. Engl. J. Med 361, 1651\u20131661 (2009).","journal-title":"N. Engl. J. Med"},{"key":"1383_CR25","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","volume":"84","author":"Z Gan-Or","year":"2015","unstructured":"Gan-Or, Z. et al. Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology 84, 880\u2013887 (2015).","journal-title":"Neurology"},{"key":"1383_CR26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/mds.29314","volume":"38","author":"SC Parlar","year":"2023","unstructured":"Parlar, S. C., Grenn, F. P., Kim, J. J., Baluwendraat, C. & Gan-Or, Z. Classification of GBA1 variants in Parkinson\u2019s disease; the GBA1-PD browser. Mov. Disord. 38, 489\u2013495 (2023).","journal-title":"Mov. Disord."},{"key":"1383_CR27","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000104","volume":"2","author":"V Mallett","year":"2016","unstructured":"Mallett, V. et al. GBA p.T369M substitution in Parkinson disease: polymorphism or association? A meta-analysis. Neurol. Genet 2, e104 (2016).","journal-title":"Neurol. Genet"},{"key":"1383_CR28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/mds.25248","volume":"28","author":"R Duran","year":"2013","unstructured":"Duran, R. et al. The glucocerobrosidase E326K variant predisposes to Parkinson\u2019s disease, but does not cause Gaucher\u2019s disease. Mov. Disord. 28, 232\u2013236 (2013).","journal-title":"Mov. Disord."},{"key":"1383_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5028","volume":"5","author":"DC Sch\u00f6ndorf","year":"2014","unstructured":"Sch\u00f6ndorf, D. C. et al. iPSC-derived neurons from GBA1-associated Parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis. Nat. Commun. 5, 4028 (2014).","journal-title":"Nat. Commun."},{"key":"1383_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.nbd.2015.06.008","volume":"82","author":"G Ambrosi","year":"2015","unstructured":"Ambrosi, G. et al. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson\u2019s disease cells. Neurobiol. Dis. 82, 235\u2013242 (2015).","journal-title":"Neurobiol. Dis."},{"key":"1383_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/srep31380","volume":"6","author":"A Sanchez-Martinez","year":"2016","unstructured":"Sanchez-Martinez, A. et al. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Sci. Rep. 6, 31380 (2016).","journal-title":"Sci. Rep."},{"key":"1383_CR32","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.12688\/f1000research.12090.1","volume":"6","author":"LM Collins","year":"2017","unstructured":"Collins, L. M., Drouin-Ouellet, J., Kuan, W.-L., Cox, T. & Barker, R. A. Dermal fibroblasts from patients with Parkinson\u2019s disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations. F1000Res 6, 1751 (2017).","journal-title":"F1000Res"},{"key":"1383_CR33","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/brain\/awab371","volume":"145","author":"C Galvagnion","year":"2022","unstructured":"Galvagnion, C. et al. Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote \u03b1-synuclein aggregation. Brain 145, 1038\u20131051 (2022).","journal-title":"Brain"},{"key":"1383_CR34","doi-asserted-by":"publisher","first-page":"e0118771","DOI":"10.1371\/journal.pone.0118771","volume":"10","author":"Y Sun","year":"2015","unstructured":"Sun, Y. et al. Properties of neurons derived from induced pluripotent stem cells of gaucher disease type 2 patient fibroblasts: potential role in neuropathology. PLoS ONE 10, e0118771 (2015).","journal-title":"PLoS ONE"},{"key":"1383_CR35","doi-asserted-by":"publisher","first-page":"104620","DOI":"10.1016\/j.nbd.2019.104620","volume":"134","author":"S Yang","year":"2020","unstructured":"Yang, S., Gegg, M., Chau, D. & Schapira, A. Glucocerebrosidase activity, cathepsin D and monomeric \u03b1-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation. Neurobiol. Dis. 134, 104620 (2020).","journal-title":"Neurobiol. Dis."},{"key":"1383_CR36","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.stemcr.2017.01.011","volume":"8","author":"S-Y Yang","year":"2017","unstructured":"Yang, S.-Y., Beavan, M., Chau, K.-Y., Taanman, J.-W. & Schapira, A. H. V. A human neural crest stem cell-derived dopaminergic neuronal model recapitulates biochemical abnormalities in GBA1 mutation carriers. Stem Cell Rep. 8, 728\u2013742 (2017).","journal-title":"Stem Cell Rep."},{"key":"1383_CR37","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","volume":"6","author":"HJR Fernandes","year":"2016","unstructured":"Fernandes, H. J. R. et al. ER stress and autophagic perturbations lead to elevated extracellular \u03b1-synuclein in GBA-N370S Parkinson\u2019s iPSC-derived dopamine neurons. Stem Cell Rep. 6, 342\u2013356 (2016).","journal-title":"Stem Cell Rep."},{"key":"1383_CR38","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.celrep.2014.10.023","volume":"9","author":"CM Woodard","year":"2014","unstructured":"Woodard, C. M. et al. iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson\u2019s disease. Cell Rep. 9, 1173\u20131182 (2014).","journal-title":"Cell Rep."},{"key":"1383_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau6870","volume":"11","author":"LF Burbulla","year":"2019","unstructured":"Burbulla, L. F. et al. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson\u2019s disease. Sci. Transl. Med. 11, eaau6870 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1383_CR40","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/acn3.177","volume":"2","author":"EM Rocha","year":"2015","unstructured":"Rocha, E. M. et al. Progressive decline of glucocerebrosidase in aging and Parkinson\u2019s disease. Ann. Clin. Transl. Neurol. 2, 433\u2013438 (2015).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1383_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0339-z","volume":"14","author":"M Huebecker","year":"2019","unstructured":"Huebecker, M. et al. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson\u2019s disease. Mol. Neurodegener. 14, 40 (2019).","journal-title":"Mol. Neurodegener."},{"key":"1383_CR42","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.23614","volume":"72","author":"ME Gegg","year":"2012","unstructured":"Gegg, M. E. et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann. Neurol. 72, 455\u2013463 (2012).","journal-title":"Ann. Neurol."},{"key":"1383_CR43","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/brain\/awt367","volume":"137","author":"KE Murphy","year":"2014","unstructured":"Murphy, K. E. et al. Reduced glucocerebrosidase is associated with increased \u03b1-synuclein in sporadic Parkinson\u2019s disease. Brain 137, 834\u2013848 (2014).","journal-title":"Brain"},{"key":"1383_CR44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.nbd.2018.09.015","volume":"121","author":"AL G\u00fcndner","year":"2019","unstructured":"G\u00fcndner, A. L. et al. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing \u03b1-synuclein levels. Neurobiol. Dis. 121, 205\u2013213 (2019).","journal-title":"Neurobiol. Dis."},{"key":"1383_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-022-00363-2","volume":"8","author":"S Blumenreich","year":"2022","unstructured":"Blumenreich, S. et al. Elevation of gangliosides in four brain regions from Parkinson\u2019s disease patients with a GBA mutation. npj Parkinsons Dis. 8, 1\u201311 (2022).","journal-title":"npj Parkinsons Dis."},{"key":"1383_CR46","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/mds.25729","volume":"29","author":"SK Abbott","year":"2014","unstructured":"Abbott, S. K. et al. Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson\u2019s disease. Mov. Disord. 29, 518\u2013526 (2014).","journal-title":"Mov. Disord."},{"key":"1383_CR47","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/BF00296485","volume":"88","author":"H Braak","year":"1994","unstructured":"Braak, H. et al. Amygdala pathology in Parkinson\u2019s disease. Acta Neuropathol. 88, 493\u2013500 (1994).","journal-title":"Acta Neuropathol."},{"key":"1383_CR48","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1093\/brain\/awf251","volume":"125","author":"AJ Harding","year":"2002","unstructured":"Harding, A. J., Stimson, E., Henderson, J. M. & Halliday, G. M. Clinical correlates of selective pathology in the amygdala of patients with Parkinson\u2019s disease. Brain 125, 2431\u20132445 (2002).","journal-title":"Brain"},{"key":"1383_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0787-2","volume":"7","author":"ZA Sorrentino","year":"2019","unstructured":"Sorrentino, Z. A. et al. Unique \u03b1-synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression. Acta Neuropathol. Commun. 7, 142 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"1383_CR50","first-page":"7","volume":"5","author":"S Dasgupta","year":"2017","unstructured":"Dasgupta, S. & Ray, S. K. Diverse biological functions of sphingolipids in the CNS: ceramide and sphingosine regulate myelination in developing brain but stimulate demyelination during pathogenesis of multiple sclerosis. J. Neurol. Psychol 5, 7 (2017).","journal-title":"J. Neurol. Psychol"},{"key":"1383_CR51","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/bs.pmbts.2017.12.009","volume":"156","author":"RW Ledeen","year":"2018","unstructured":"Ledeen, R. W. & Wu, G. Gangliosides, \u03b1-synuclein, and Parkinson\u2019s disease. Prog. Mol. Biol. Transl. Sci. 156, 435\u2013454 (2018).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"1383_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-024-00632-2","volume":"10","author":"Y Fu","year":"2024","unstructured":"Fu, Y. et al. A protective role of ABCA5 in response to elevated sphingomyelin levels in Parkinson\u2019s disease. npj Parkinsons Dis. 10, 1\u201312 (2024).","journal-title":"npj Parkinsons Dis."},{"key":"1383_CR53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.plipres.2016.03.006","volume":"63","author":"M-S Wegner","year":"2016","unstructured":"Wegner, M.-S., Schiffmann, S., Parnham, M. J., Geisslinger, G. & Gr\u00f6sch, S. The enigma of ceramide synthase regulation in mammalian cells. Prog. Lipid Res 63, 93\u2013119 (2016).","journal-title":"Prog. Lipid Res"},{"key":"1383_CR54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrm.2017.107","volume":"19","author":"YA Hannun","year":"2018","unstructured":"Hannun, Y. A. & Obeid, L. M. Sphingolipids and their metabolism in physiology and disease. Nat. Rev. Mol. Cell Biol. 19, 175\u2013191 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1383_CR55","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1529\/biophysj.105.067371","volume":"90","author":"PS Niemel\u00e4","year":"2006","unstructured":"Niemel\u00e4, P. S., Hyv\u00f6nen, M. T. & Vattulainen, I. Influence of chain length and unsaturation on sphingomyelin bilayers. Biophys. J. 90, 851\u2013863 (2006).","journal-title":"Biophys. J."},{"key":"1383_CR56","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1529\/biophysj.105.075150","volume":"90","author":"A Filippov","year":"2006","unstructured":"Filippov, A., Or\u00e4dd, G. & Lindblom, G. Sphingomyelin structure influences the lateral diffusion and raft formation in lipid bilayers. Biophys. J. 90, 2086\u20132092 (2006).","journal-title":"Biophys. J."},{"key":"1383_CR57","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1111\/jnc.16114","volume":"168","author":"G Onal","year":"2024","unstructured":"Onal, G. et al. Variant-specific effects of GBA1 mutations on dopaminergic neuron proteostasis. J. Neurochem. 168, 2543\u20132560 (2024).","journal-title":"J. Neurochem."},{"key":"1383_CR58","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.cellsig.2007.12.006","volume":"20","author":"K Kitatani","year":"2008","unstructured":"Kitatani, K., Idkowiak-Baldys, J. & Hannun, Y. A. The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal. 20, 1010\u20131018 (2008).","journal-title":"Cell Signal."},{"key":"1383_CR59","doi-asserted-by":"publisher","first-page":"26167","DOI":"10.1074\/jbc.M311591200","volume":"279","author":"D Vruchte","year":"2004","unstructured":"Vruchte, D. et al. Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport. J. Biol. Chem. 279, 26167\u201326175 (2004).","journal-title":"J. Biol. Chem."},{"key":"1383_CR60","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.nbd.2004.05.002","volume":"16","author":"RH Lachmann","year":"2004","unstructured":"Lachmann, R. H. et al. Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiol. Dis. 16, 654\u2013658 (2004).","journal-title":"Neurobiol. Dis."},{"key":"1383_CR61","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrm2330","volume":"9","author":"G van Meer","year":"2008","unstructured":"van Meer, G., Voelker, D. R. & Feigenson, G. W. Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol. 9, 112\u2013124 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1383_CR62","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.tem.2021.01.006","volume":"32","author":"M Falabella","year":"2021","unstructured":"Falabella, M., Vernon, H. J., Hanna, M. G., Claypool, S. M. & Pitceathly, R. D. S. Cardiolipin, mitochondria, and neurological disease. Trends Endocrinol. Metab. 32, 224\u2013237 (2021).","journal-title":"Trends Endocrinol. Metab."},{"key":"1383_CR63","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/mds.27119","volume":"32","author":"P Garc\u00eda-Sanz","year":"2017","unstructured":"Garc\u00eda-Sanz, P. et al. N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson\u2019s disease. Mov. Disord. 32, 1409\u20131422 (2017).","journal-title":"Mov. Disord."},{"key":"1383_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2012.10.010","volume":"62","author":"MWJ Cleeter","year":"2013","unstructured":"Cleeter, M. W. J. et al. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem. Int. 62, 1\u20137 (2013).","journal-title":"Neurochem. Int."},{"key":"1383_CR65","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1016\/j.celrep.2018.05.009","volume":"23","author":"DC Sch\u00f6ndorf","year":"2018","unstructured":"Sch\u00f6ndorf, D. C. et al. The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson\u2019s disease. Cell Rep. 23, 2976\u20132988 (2018).","journal-title":"Cell Rep."},{"key":"1383_CR66","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13024-022-00555-7","volume":"17","author":"M Lang","year":"2022","unstructured":"Lang, M., Pramstaller, P. P. & Pichler, I. Crosstalk of organelles in Parkinson\u2019s disease\u2014MiT family transcription factors as central players in signaling pathways connecting mitochondria and lysosomes. Mol. Neurodegener. 17, 50 (2022).","journal-title":"Mol. Neurodegener."},{"key":"1383_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109898","volume":"37","author":"H Penkert","year":"2021","unstructured":"Penkert, H. et al. Proteomic and lipidomic profiling of demyelinating lesions identifies fatty acids as modulators in lesion recovery. Cell Rep. 37, 109898 (2021).","journal-title":"Cell Rep."},{"key":"1383_CR68","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ymgme.2013.12.003","volume":"111","author":"EI Ginns","year":"2014","unstructured":"Ginns, E. I. et al. Neuroinflammation and \u03b1-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction. Mol. Genet. Metab. 111, 152\u2013162 (2014).","journal-title":"Mol. Genet. Metab."},{"key":"1383_CR69","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adk8249","volume":"17","author":"R Wang","year":"2024","unstructured":"Wang, R. et al. Glucosylceramide accumulation in microglia triggers STING-dependent neuroinflammation and neurodegeneration in mice. Sci. Signal. 17, eadk8249 (2024).","journal-title":"Sci. Signal."},{"key":"1383_CR70","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1089\/ars.2015.6307","volume":"23","author":"EM Rocha","year":"2015","unstructured":"Rocha, E. M. et al. Sustained systemic glucocerebrosidase inhibition induces brain \u03b1-synuclein aggregation, microglia and complement C1q activation in mice. Antioxid. Redox Signal. 23, 550\u2013564 (2015).","journal-title":"Antioxid. Redox Signal."},{"key":"1383_CR71","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.freeradbiomed.2017.04.363","volume":"111","author":"M Xiao","year":"2017","unstructured":"Xiao, M., Zhong, H., Xia, L., Tao, Y. & Yin, H. Pathophysiology of mitochondrial lipid oxidation: Role of 4-hydroxynonenal (4-HNE) and other bioactive lipids in mitochondria. Free Radic. Biol. Med 111, 316\u2013327 (2017).","journal-title":"Free Radic. Biol. Med"},{"key":"1383_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108132","volume":"32","author":"D Fitzner","year":"2020","unstructured":"Fitzner, D. et al. Cell-type- and brain-region-resolved mouse brain lipidome. Cell Rep. 32, 108132 (2020).","journal-title":"Cell Rep."},{"key":"1383_CR73","doi-asserted-by":"publisher","first-page":"106101","DOI":"10.1016\/j.parkreldis.2024.106101","volume":"122","author":"J Horsager","year":"2024","unstructured":"Horsager, J. & Borghammer, P. Brain-first vs. body-first Parkinson\u2019s disease: an update on recent evidence. Park. Relat. Disord. 122, 106101 (2024).","journal-title":"Park. Relat. Disord."},{"key":"1383_CR74","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1021\/jasms.9b00136","volume":"31","author":"I\u00d8 Nielsen","year":"2020","unstructured":"Nielsen, I. \u00d8 et al. Comprehensive evaluation of a quantitative shotgun lipidomics platform for mammalian sample analysis on a high-resolution mass spectrometer. J. Am. Soc. Mass Spectrom. 31, 894\u2013907 (2020).","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"1383_CR75","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa, F. et al. Scikit-learn: machine learning in Python. J. Mach. Learn. Res. 12, 2825\u20132830 (2011).","journal-title":"J. Mach. Learn. Res."},{"key":"1383_CR76","unstructured":"Jekel, C. F. & Venter, G. pwlf: A Python Library for Fitting 1D Continuous Piecewise Linear Functions. https:\/\/github.com\/cjekel\/piecewise_linear_fit_py"},{"key":"1383_CR77","doi-asserted-by":"crossref","unstructured":"Seabold, S. & Perktold, J. Statsmodels: Econometric and Statistical Modeling with Python. scipy (2010).","DOI":"10.25080\/Majora-92bf1922-011"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01383-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01383-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01383-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:02:39Z","timestamp":1784505759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01383-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1383"],"URL":"https:\/\/doi.org\/10.1038\/s41531-026-01383-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.11.617800","asserted-by":"object"}]},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.B. is an Editorial Board Member of npj Parkinson\u2019s Disease. He was not involved in the journal\u2019s review of, or decisions related to, this manuscript.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"174"}}